BDRX - חוב כולל להון Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals (BDRX) specializes in combating brain tumors, yet faces a funding shortage and the threat of trial disruptions, necessitating new investments. This chart of the company's market valuation on GURU.Markets confirms this, demonstrating the 0.00 metric. Meanwhile, the firm is implementing wastewater treatment and energy saving in accordance with ESG standards, while the humanitarian status of biomedicine shields it from the impact of global political strife.

For the small biotech company Biodexa Pharmaceuticals (BDRX), which develops oncology drug delivery systems, maintaining a balance between debt and equity is critically important. This indicator measures the total debt load relative to net assets, allowing investors to assess financial stability and bankruptcy risk. The trend of total debt relative to equity helps determine whether excessive leverage could lead to a loss of control over the business.